CLINICAL RESPONSE TO FLUVASTATIN: CLINICAL EXOME PANEL (Sec. & CNVs) – 2 genes

The Fluvastatin Clinical Response Panel is designed to analyze genetic variants that influence metabolism, lipid-lowering efficacy, and the risk of muscle-related adverse effects associated with statin therapy. Genetic differences in hepatic metabolizing enzymes and transporters can modify drug bioavailability and elimination, affecting therapeutic response and treatment safety. The study includes the CYP2C9 gene, the main enzyme responsible for the hepatic metabolism of fluvastatin, variants of which can alter the drug clearance rate, and the SLCO1B1 gene, which encodes a key hepatic transporter (OATP1B1) involved in the uptake of statins from plasma into the liver. Certain polymorphisms in SLCO1B1 are associated with an increased risk of statin-induced myopathy. This panel allows for dose adjustment, prevention of muscle-related adverse effects, and improved efficacy of lipid-lowering therapy through personalized pharmacogenetic prescribing. Key genes analyzed: CYP2C9 and SLCO1B1. You can consult the complete list of genes analyzed by contacting Genotica.